PubMed-Indexed Clinical Study Demonstrates Superior Results vs. the Leading Prescription Standard of Care for Rosacea, Highlighting the Potential for Better Outcomes and More Affordable Healthcare
MIAMI BEACH, Fla., July 23, 2026 /PRNewswire/ — Crescel LLC, a Florida-based progressive science and expertise firm, at this time introduced publication of its landmark PubMed-indexed, peer-reviewed scientific examine exhibiting that its biobotanical expertise produced statistically vital enhancements over the main prescription normal of take care of rosacea in a randomized, double-blind, managed scientific trial. Published within the Journal of Cosmetic Dermatology, the examine represents a serious scientific milestone for the corporate’s pioneering proprietary microemulsion expertise platform and a big development in formulation science.
The examine demonstrated statistically vital enhancements in facial redness and inflammatory lesions, with Crescel® Skin Renewal Cream decreasing facial redness by 54% in contrast with 23% for the prescription normal of care and inflammatory lesions by 74% in contrast with 17%, whereas demonstrating an wonderful security profile, with no unfavourable unintended effects noticed.
Rosacea impacts greater than 400 million folks worldwide, making it some of the widespread persistent inflammatory pores and skin circumstances. Beyond its scientific findings, Crescel believes the publication demonstrates the broader potential of American-developed, non-pharmaceutical healthcare improvements to enhance well being outcomes whereas serving to tackle one of many nation’s most urgent challenges—healthcare affordability.
“Healthcare systems around the world are searching for innovative solutions that improve outcomes while reducing long-term costs,” stated Peter J. Passalacqua, Jr., Co-Founder, Chairman & CEO of Crescel. “Our peer-reviewed publication validates years of scientific research and reinforces our belief that breakthrough biobotanical technologies can play an increasingly important role in the future of healthcare.”
Beyond the revealed scientific trial, Crescel has additionally demonstrated promising real-world scientific outcomes throughout a number of high-cost pores and skin circumstances, additional reinforcing the broader potential of its proprietary microemulsion expertise platform.
“This is one of the most exciting medical advancements I have seen in my 30 years of practicing rehabilitation medicine,” stated Dr. Roberta Shapiro, Assistant Clinical Professor, Columbia University Medical Center, Department of Rehabilitation and Regenerative Medicine, and Chief Medical Officer of Crescel. “Crescel’s healing capabilities are exceptional. This innovative technology has the potential to improve care while expanding access to safe, effective, non-pharmaceutical options.”
The full examine, “Efficacy, Tolerance, and Safety of a Novel Botanical Anti-Inflammatory Moisturizer in Rosacea: Results From a Double-Blinded, Randomized Controlled Trial,” is out there by PubMed and the Journal of Cosmetic Dermatology.
Study Links
Journal of Cosmetic Dermatology (Full Publication):
https://onlinelibrary.wiley.com/doi/10.1111/jocd.70910
PubMed Index:
https://pubmed.ncbi.nlm.nih.gov/42163060/
For extra details about Crescel, go to www.crescel.com.
SOURCE Crescel LLC
